Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort

Veer B Gupta; Andrea C Wilson; Samantha Burnham; Eugene Hone; Steve Pedrini; Simon M Laws; Wei Ling Florence Lim; Alan Rembach; Stephanie Rainey-Smith; David Ames; Lynne Cobiac; S Lance Macaulay; Colin L Masters; Christopher C Rowe; Ashley I Bush; Ralph N Martins

Journal article

Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort

Veer B Gupta, Andrea C Wilson, Samantha Burnham, Eugene Hone, Steve Pedrini, Simon M Laws, Wei Ling Florence Lim, Alan Rembach, Stephanie Rainey-Smith, David Ames, Lynne Cobiac, S Lance Macaulay, Colin L Masters, Christopher C Rowe, Ashley I Bush, Ralph N Martins

ALZHEIMERS RESEARCH & THERAPY | BIOMED CENTRAL LTD | Published : 2015

DOI: 10.1186/s13195-015-0105-6

Download PDF

Abstract

INTRODUCTION: Alzheimer's disease (AD) is a growing socioeconomic problem worldwide. Early diagnosis and prevention of this devastating disease have become a research priority. Consequently, the identification of clinically significant and sensitive blood biomarkers for its early detection is very important. Apolipoprotein E (APOE) is a well-known and established genetic risk factor for late-onset AD; however, the impact of the protein level on AD risk is unclear. We assessed the utility of plasma ApoE protein as a potential biomarker of AD in the large, well-characterised Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) cohort. METHODS: Total plasma ApoE levels were measu..

View full abstract

University of Melbourne Researchers

Ashley Bush Author Florey Department of Neuroscience and Mental Health

Colin Masters Author Florey Department of Neuroscience and Mental Health

Christopher Rowe Author Florey Department of Neuroscience and Mental Health

David Ames Author Psychiatry

Related Projects (1)

TRANSLATIONAL THERAPEUTICS AND DIAGNOSTICS FOR ALZHEIMER'S DISEASE

nan

Grants

Awarded by National Health and Medical Research Council (NHMRC) Australia via the Dementia Collaborative Research Centres (DCRC) program

Funding Acknowledgements

Core funding for this study was provided by CSIRO, which was supplemented by "in-kind" contributions from study partners. This research is supported by the Science and Industry Endowment Fund (www.SIEF.org.au). The AIBL investigators thank Richard Head of CSIRO for initiating and facilitating the AIBL collaboration. The study also received support from the National Health and Medical Research Council (NHMRC) Australia via the Dementia Collaborative Research Centres (DCRC) program and through a project grant (APP1009292) awarded to RNM, SML and VBG. The authors also acknowledge the financial support of the Cooperative Research Centre (CRC) for Mental Health, an Australian Government Initiative. The McCusker Alzheimers Research Foundation Inc contributed financial and in kind support to AIBL. We kindly thank all AIBL Research Group members (http://aibl.csiro.au/about/aibl-research-team/) and those who took part as subjects in the study for their commitment and dedication to helping advance research into the early detection and causation of AD.